Literature DB >> 1359539

Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

R J Epstein1, B J Druker, T M Roberts, C D Stiles.   

Abstract

We inoculated rabbits with synthetic phosphopeptides, duplicating a major autophosphorylation site of the c-erbB-2 protooncogene product. The rabbits produced antisera that, after reverse immunoaffinity purification, selectively recognize the erbB-2 protein in its enzymatically active configuration. These anti-phosphopeptide antisera identify a subset of erbB-2-positive human cell lines wherein the protein is constitutively active as a tyrosine kinase. Synthetic phosphopeptides incorporating informative protein phosphorylation sites may prove useful for generating antibodies that indicate the activation state of additional tyrosine kinases and perhaps other proteins phosphorylated on serine and threonine residues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359539      PMCID: PMC50353          DOI: 10.1073/pnas.89.21.10435

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Isolation of antibodies for phosphotyrosine by immunization with a v-abl oncogene-encoded protein.

Authors:  J Y Wang
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

2.  Immunodetection of the ligand-activated receptor for epidermal growth factor.

Authors:  R Campos-González; J R Glenney
Journal:  Growth Factors       Date:  1991       Impact factor: 2.511

3.  Ligand activation causes a phosphorylation-dependent change in platelet-derived growth factor receptor conformation.

Authors:  M T Keating; J A Escobedo; L T Williams
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

Review 4.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

Authors:  S K Hanks; A M Quinn; T Hunter
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

5.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

6.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

7.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

Authors:  N R Lemoine; S Staddon; C Dickson; D M Barnes; W J Gullick
Journal:  Oncogene       Date:  1990-02       Impact factor: 9.867

8.  Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.

Authors:  J A Cohen; D B Weiner; K F More; Y Kokai; W V Williams; H C Maguire; V A LiVolsi; M I Greene
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

9.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

10.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3.

Authors:  C R King; I Borrello; F Bellot; P Comoglio; J Schlessinger
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

View more
  11 in total

1.  Extracting functional information from tissues.

Authors:  M P DiGiovanna
Journal:  Mol Diagn       Date:  2001-03

Review 2.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

3.  Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.

Authors:  M I Wahl; A C Fluckiger; R M Kato; H Park; O N Witte; D J Rawlings
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

4.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

5.  Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.

Authors:  G C Huang; X Ouyang; R J Epstein
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

6.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Authors:  X Ouyang; T Gulliford; H Zhang; G Smith; G Huang; R J Epstein
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

7.  Activation of ErbB2 during wallerian degeneration of sciatic nerve.

Authors:  Y K Kwon; A Bhattacharyya; J A Alberta; W V Giannobile; K Cheon; C D Stiles; S L Pomeroy
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

8.  Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail.

Authors:  A Bishayee; L Beguinot; S Bishayee
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

9.  Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.

Authors:  S S Bacus; D Chin; Y Yarden; C R Zelnick; D F Stern
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

10.  Dynamics of human keratin 18 phosphorylation: polarized distribution of phosphorylated keratins in simple epithelial tissues.

Authors:  J Liao; L A Lowthert; N O Ku; R Fernandez; M B Omary
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.